Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 5, 2015, Pages 851-860

  Mota, P ^a   Silva, H C ^a   Soares, M J ^a   Pego, A ^a   Loureiro, M ^a   Cordeiro, C Robalo ^a   Regateiro, F J ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Alcohol consumption; Lung cancer; Polymorphisms; Sex; Smoking habits

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYP1A1 PROTEIN, HUMAN; CYTOCHROME P450 1A1; CYTOCHROME P450 2D6; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; NAT2 PROTEIN, HUMAN;

ADULT; ADVERSE EFFECTS; AGED; CANCER STAGING; CASE CONTROL STUDY; DRINKING BEHAVIOR; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PORTUGAL; QUESTIONNAIRE; RISK; RISK FACTOR; SEX DIFFERENCE; SMOKING; STATISTICAL MODEL; SURVIVAL;

ADULT; AGED; ALCOHOL DRINKING; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; FEMALE; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, GENETIC; PORTUGAL; QUESTIONNAIRES; RISK FACTORS; SEX FACTORS; SMOKING; SURVIVAL ANALYSIS;

EID: 84931373676     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1868-z     Document Type: Article

References (41)

1. Benedetti A, Parent ME, Siemiatycki J (2006) Consumption of alcoholic beverages and risk of lung cancer: results from two case-control studies in Montreal, Canada. Cancer Causes Control 17:469–480
2. Bertram J, Rogers A (1981) Recovery of bronchial epithelium on stopping smoking. Br Med J 283:1567–1569
3. Board P, Menon D (2013) Glutathione transferases, regulators of cellular metabolism and physiology. Biochim Biophys Acta 1830:3267–3288
4. Borlak J, Reamon-Buettner S (2006) N.Acetyltransferases 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet 7:58. doi:10.1186/1471-2350-7-58
5. Božina N, Bradamante V, Lovrić M (2009) Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 60:217–242
6. Carlsten C, Saggo GS, Frodshem AJ, Burke W, Higgins JP (2008) Glutathione S-Transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis. Am J Epidemiol 167:759–774
7. Chen Z, Li Z, Niu X, Yu Y, Lu S (2011) The effect of CYP1A1 polymorphism on the risk of lung cancer: a global meta-analysis based on 71 case-control studies. Mutagenesis 26:437–446
8. Christensen PM, Gotzsche PC, Brosen K (1997) The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol 51:389–393
9. Cohen S, Paré P, Man S, Sin D (2007) The growing burden of chronic obstructive pulmonary disease and lung cancer in women. Am J Respir Crit Care Med 176:113–120
10. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403
11. Freudenheim JL, Ritz J, Smith-Warner SA, Albanes D, Bandera EV, van den Brandt P, Colditz G, Feskanich D, Goldbohm RA, Harnack L, Miller A, Rimm E, Rohan T, Sellers T, Virtamo J, Willett W, Hunter D (2005) Alcohol consumption and risk of lung cancer: a pooled analysis of cohort studies. Am J Clin Nutr 82:657–667
12. Gao CM, Takezaki T, Wu JZ, Li ZY, Liu YT, Li SP et al (2002) Glutathione S-Transferase M1 (GSTM1) and GSTT1 genotype, smoking, consumption of alcohol and tea and risk of esophageal and stomach cancers: a case control study of a high incidence area in Jiangsu Province, China. Cancer Lett 188:95–102
13. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbeum M, Wolf CR (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Reprinted from Nature, Macmillan Magazines Ltd 347:773–776
14. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R, Kadlubar F (1999) Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomark Prev 8:683–692
15. Hayashi S, Watanabe J, Nakachi K, Kawajiri K (1991) Genetic linkage of lung cancer –associated Msp1 polymorphism with aminoacid replacement in the heme binding region of the human cytochrome P450 1A1 gene. J Biochem 110:407–411
16. Hayes J, Strange R (2000a) Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61:154–166
17. Hayes J, Strange R (2000b) Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61:154–166
18. Hecht SS (2002) Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet oncol 3:461–469
19. Holley S, Fryer A, Haycock J, Grubb A, Strange R, Hoban P (2007) Differential effects of glutathione S-transferase pi (GSTP1) haplotypes on cell proliferation and apoptosis. Carcinogenesis 28(11):2268–2273
20. Josephy P (2010) Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology. Hum Genomics Proteomics 2010:876940
21. Kawajiri K, Nakachi K, Imai K et al (1990a) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450 1A1 gene. FEBS Lett 263:131–133
22. Kawajiri K, Nakachi K, Imai K et al (1990b) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett 263:131–133
23. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 14:77–87
24. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K (1991) Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 51:5177–5180
25. North C, Christiani D (2013) Women and lung cancer: what is new? Semin Thorac Surg 25:87–94
26. Pallis A, Syrigos K (2013) Lung cancer in never smokers: disease characteristics and risk factors. Crit Rev Oncol/Hematol 88:494–503
27. Parsons A, Daley A, Begh R, Aveyard P (2010) Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis. Systematic review of observational studies with meta-analysis. BMJ 340:b5569. doi:10.1136/bmj.b5569
28. Pool-Zobel B, Veeriah S, Böhmer FD (2005) Modulation of xenobiotic metabolizing enzymes by anticarcinogens—focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis. Mutat Res 591(1–2):74–92
29. Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S (2013) Polymorphic cytochrome P450 enzymes (Cyps) and their role in personalized therapy. PLoS ONE 8(12):e82562. doi:10.1371/journal.pone.0082562
30. Ritchie K, Henderson C, Wang X, Vassieva O, Carrie D et al (2007) Glutathione transferase plays a critical role in the development of lung carcinogenesis following exposure to tobacco-related carcinogens and urethane. Cancer Res 67:9248–9257
31. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics 8:227–238
32. Saxena A, Dhillon VS, Shahid M, Khalil HS et al (2012) GSTP1 methylation and polymorphism increase the risk of breast cancer and the effects of diet and lifestyle in breast cancer patients. Exp Ther Med 4(6):1097–1103 PMCID: PMC3494109
33. Seyfried T, Shelton L (2010) Cancer as a metabolic disease. Nutr Metab 7:7
34. Siegfried JM (2001) Women and lung cancer: does oestrogen play a role? Lancet Oncol 2:506–513
35. Smith C, Wadelius M, Gough A, Harrisson D, Wolf C, Rane A (1997) A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 34:758–760
36. Sreejal Syamola V, Hariharan S et al (2005) Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population. J Hum Genet 50:618–627
37. Sweeney C, Nazar-Stewart V, Stapleton P, Eaton D, Vaughan T (2003) Glutathione S-transferase M1, T1 and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomark Prev 12:527–533
38. Tyczynski J, Bray F, Parkin DM (2003) Lung cancer in Europe in 2000: epidemiology, prevention and early detection. Lancet oncol 4:45–55
39. Wright CM, Larsen JE, Colosimo ML, Barr JJ, Chen L, McLachlan RE, Yang IA, Bowman RV, Fong KM (2010) Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in non small cell lung cancer. Eur Respir J 35:152–159
40. Wu J, Sin D (2011) Improved patient outcome with smoking cessation: when is it too late? Int J COPD 6:259–267
41. Zanger U, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities and impact of genetic variation. Pharmacol Ther 138:103–141